Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -32.91% is 59% below its 5-year average of -20.66%, near the low end of its 5-year range (-32.91%–-9.10%).
30.29% below its 12-month average of -25.26%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -9.37%.
RETURN ON ASSETS (ROA)
-32.91%
RETURN ON ASSETS (ROA) AVG TTM
-25.26%
RETURN ON ASSETS (ROA) AVG 3Y
-23.04%
RETURN ON ASSETS (ROA) AVG 5Y
-20.66%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-30.29%
CURRENT VS 3Y AVG
-42.84%
CURRENT VS 5Y AVG
-59.33%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-26.45%
median of 509 covered companies
CURRENT VS SECTOR MEDIAN
-24.42%
vs the sector median at left
Design Therapeutics, Inc.
Market Cap
$776.65M
Return on Assets (ROA)
-32.91%
TTM Avg
-25.26%
3Y Avg
-23.04%
5Y Avg
-20.66%
Market Cap
$774.54M
Return on Assets (ROA)
-36.55%
TTM Avg
-44.22%
3Y Avg
-44.22%
5Y Avg
-44.22%
Market Cap
$769.83M
Return on Assets (ROA)
-13.47%
TTM Avg
-22.22%
3Y Avg
-41.40%
5Y Avg
-40.82%
Market Cap
$785.03M
Return on Assets (ROA)
-5.26%
TTM Avg
0.19%
3Y Avg
-3.34%
5Y Avg
-3.22%
Market Cap
$766.41M
Return on Assets (ROA)
-20.44%
TTM Avg
-45.26%
3Y Avg
-91.41%
5Y Avg
-102.66%
Market Cap
$791.64M
Return on Assets (ROA)
-18.03%
TTM Avg
-7.81%
3Y Avg
-4.40%
5Y Avg
-1.35%
Market Cap
$756.15M
Return on Assets (ROA)
-42.53%
TTM Avg
-41.06%
3Y Avg
-49.54%
5Y Avg
-47.47%
Market Cap
$812.78M
Return on Assets (ROA)
10.76%
TTM Avg
17.66%
3Y Avg
20.82%
5Y Avg
23.86%
Market Cap
$737.02M
Return on Assets (ROA)
-38.01%
TTM Avg
-251.96%
3Y Avg
-211.47%
5Y Avg
-174.45%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Design Therapeutics, Inc. (DSGN) | $776.65M | -32.91% | -25.26% | -23.04% | -20.66% |
| Attovia Therapeutics, Inc. (ATTO)vs › | $774.54M | -36.55% | -44.22% | -44.22% | -44.22% |
| Geron Corporation (GERN)vs › | $769.83M | -13.47% | -22.22% | -41.40% | -40.82% |
| AdaptHealth Corp. (AHCO)vs › | $785.03M | -5.26% | 0.19% | -3.34% | -3.22% |
| Avalo Therapeutics, Inc. (AVTX)vs › | $766.41M | -20.44% | -45.26% | -91.41% | -102.66% |
| Cytek Biosciences, Inc. (CTKB)vs › | $791.64M | -18.03% | -7.81% | -4.40% | -1.35% |
| Candel Therapeutics, Inc. (CADL)vs › | $756.15M | -42.53% | -41.06% | -49.54% | -47.47% |
| InMode Ltd. (INMD)vs › | $812.78M | 10.76% | 17.66% | 20.82% | 23.86% |
| Anteris Technologies Global Corp. (AVR)vs › | $737.02M | -38.01% | -251.96% | -211.47% | -174.45% |
| Gyre Therapeutics, Inc. (GYRE)vs › | $825.02M | -8.70% | 6.33% | -16.09% | -46.82% |
ROA
-32.9%
ROE
-35.1%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -30.85% |
| 2024-12-31 | -19.67% |
| 2023-12-31 | -23.08% |
| 2022-12-31 | -18.56% |
| 2021-12-31 | -9.10% |
| 2020-12-31 | -22.67% |
| 2019-12-31 | -2274.44% |
